Drug, bio-affecting and body treating compositions inventions 06/07

20070149439 - Pituitary adenylate cyclase-activating polypeptide (pacap) is an anti-mitogenic signal for selected neuronal precursors in vivo: Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor system can be manipulated positively or negatively to regulate mitosis in neuronal precursor cells. The ligand/receptor system involves PACAP, PACAP receptor, PAC1, and related antagonists. The methods of regulation of the present invention may model be used to define cell cycle regulation... Agent: Licata & Tyrrell P.C.

20070149440 - Transferrin and transferrin-based compositions for diabetes treatment: Embodiments of the present invention use transferrin or active derivatives to control or stabilize abnormally elevated levels of blood glucose in mammals, particularly humans. Embodiments of the invention also provide methods for enhancing survival of islet β-cells in vivo and in vitro. In other embodiments, transferrin or active derivatives are... Agent: Faegre & Benson LLP Patent Docketing

20070149441 - Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same: Methods for chemical modification of hyaluronic acid, formation of amine or aldehyde functionalized hyaluronic acid, and the cross-linking thereof to form hydrogels are provided. Functionalized hyaluronic acid hydrogels of this invention can be polymerized in situ, are biodegradable, and can serve as a tissue adhesive, a tissue separator, a drug... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070149443 - Methods of treating obesity using enterostatin: The present invention provides methods of treating or preventing disorders or conditions associated with enterostatin deficiency by administering to a subject in need thereof an effective amount of enterostatin. The present invention also provides methods of selecting a subject for therapy with enterostatin. Exemplary disorders or conditions associated with enterostatin... Agent: Jones Day

20070149442 - Non-hygroscopic compositions of enterostatin: The present invention provides pharmaceutical compositions of enterostatin that can display advantageous hygroscopicity, advantageous stability, or both. The pharmaceutical compositions of enterostatin can be useful for the manufacture of an pharmaceutical product comprising enterostatin.... Agent: Jones Day

20070149444 - Peptides that home to tumor lymphatic vasculature and methods of using same: The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to... Agent: Mcdermott, Will & Emery

20070149445 - Aplidine for multiple myeloma treatment: Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma.... Agent: Fish & Richardson PC

20070149446 - Tamandarin analogs and fragments thereof and methods of making and using: The present invention is directed to a compound of Formula I wherein R1, R2, R3, R4, R5, R6, W, X, Y, and Z are defined herein. The compounds of the present invention are useful as anticancer agents. Specifically, the compounds are useful for treating or preventing cancer and tumor growth.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070149447 - Cyclosporin compositions: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.... Agent: Allergan, Inc.

20070149451 - Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent: The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and an antiobesity agent, or an appetite regulating agent, or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the... Agent: Novartis Corporate Intellectual Property

20070149454 - Controlled release delivery system for nasal applications and method of treatment: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma... Agent: Fitch Even Tabin And Flannery

20070149456 - Epithelial sodium channel inhibiting agents and uses therefor: Disclosed herein are peptide cleavage products, generated during natural processing of epithelial sodium channel α- and γ-subunits and their use in inhibiting epithelial sodium channel activity. Also disclosed herein are polypeptide and polypeptide analog derivatives of those agents. These epithelial sodium channel-inhibitory agents may be formulated into a drug product... Agent: Jesse A. Hirshman, Esq.

20070149450 - Method for reducing levels of c-reactive protein: A compound comprising at least a structural entity which binds C-reactive protein (CRP) or parts of it or CRP in its monomeric, pentameric or multimeric form, preferably human CRP and which a) blocks one or more CRP functions on cell surfaces or in a solution, preferably blood or other body... Agent: Jacobson Holman PLLC

20070149452 - Method of treating and/or preventing cancers and aids using sartans and/or statins to modulate vdr, and/or ppar, and/or gcr and/or cb1 receptors; in conjunction with certain bacteriostatic antibiotics: This invention is a method of killing the stealthy intra-cellular bacteria which are key to the pathogenesis of both Acquired Immune Deficiency Syndrome(s) (AIDS) and Cancers. It is currently believed that the disease(s) known as AIDS are caused by a virus, the Human Immunodeficiency Virus (HIV). But much of the... Agent: Trevor Gordon Marshall

20070149455 - Modified and stabilized gdf propeptides and uses thereof: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

20070149457 - Stable solid forms of enterostatin: The present invention provides co-complexes of enterostatin that can display advantageous hygroscopicity, advantageous stability, or both. The co-complexes of enterostatin can be useful for the manufacture of an pharmaceutical product comprising enterostatin.... Agent: Jones Day

20070149449 - Therapeutic targets in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel... Agent: Chiron Corportion

20070149453 - Treating inflammation using a biological agent that causes cells to release cytokine receptors: This disclosure describes inventions related to the use of biological agents that cause cytokine receptors to be released from the surface of cells. One aspect of this invention is based on the unexpected finding that extending the length of an exemplary agent at the N-terminus enhances expression and production of... Agent: Meyer Pharmaceuticals LLC

20070149448 - Use of the cathelicidin ll-37 and dervicaties thereof for would healing: Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by... Agent: Birch Stewart Kolasch & Birch

20070149458 - Uses of myostatin antagonists: The present invention provides methods for treating disorders arising from hypogonadism, rheumatoid cachexia, cachexia due to burns, cachexia due to administration of chemical agents, cachexia due to diabetes, diabetic nephropathy, Prader Willi syndrome, excessive TNF-α, and other muscle-related, metabolic and inflammatory disorders by administering myostatin antagonists to subjects suffering from... Agent: Amgen Inc. Law Department

20070149459 - Oxidation process for the preparation of n-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-{n-[(tert-butylamino)carbonyl]-3-methyl-l-valyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide and related compounds: e

20070149460 - Modified lysine-mimetic compounds: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070149461 - Use of canthin-6-one, plant extracts containing same and derivatives thereof in the treatment of trypanosomiases: The invention concerns the use of canthin-6-one from plant extracts containing same, in particular canthin-6-one in the form of a Zanthoxylum chiloperone of the angustifolium variety, and some of its derivatives for making a medicine for the treatment of trypanosomiases, in particularly for treating Chagas disease.... Agent: Lowe Hauptman Berner, LLP

20070149462 - Nucleotide and oligonucleotide prodrugs: which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20070149463 - Bifunctional macrolide heterocyclic compounds and methods of making and using the same: The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of bifunctional compounds useful as therapeutic agents. These compounds have both a macrolide ring and at least one heterocyclic moiety. The present invention further relates to processes... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070149464 - Combination: Compounds of formula (I) are used in combination with a second antiparasitic agent for the treatment of parasitic infestations in a host animal.... Agent: Warner-lambert Company

20070149465 - Compositions and methods for prevention and treatment of cachexia: Compositions and methods for preventing and treating wasting disorders, such as cachexia and anorexia, are provided. In one aspect, the present invention provides a method for preventing and treating a wasting disorder in a mammal. In one embodiment, the method of the invention comprises administering to such mammal a macrolide... Agent: David P. Lentini

20070149466 - Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders: Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070149472 - Antisense oligonucleotide compositions and methods for the modulation of jnk proteins: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as... Agent: Elmore Patent Law Group

20070149475 - Augmentation of wound healing by eif-4e mrna and egf mrna: There is provided a method of augmenting transient protein synthesis in a cell by delivering to the cell mRNA functionally related to protein production. Also provided is a method of augmenting transient protein synthesis in cells by increasing protein synthesis of growth factors from endogenous cellular mRNA and exogenous mRNA... Agent: Kenneth I. Kohn Kohn & Associates

20070149471 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent: Pepper Hamilton LLP One Mellon Center

20070149467 - Hypoxia inducible vegf plasmid for ischemic disease: Plasmids useful for treating ischemic disease, such as ischemic heart disease, are described. The plasmids express vascular endothelial growth factor (VEGF) under the control of a promoter (RTP801) that is up-regulated under hypoxic conditions. Pharmaceutical compositions for treating ischemic disease include mixtures of the hypoxia-regulated VEGF plasmids and pharmaceutically acceptable... Agent: Alan J. Howarth

20070149470 - Inhibition of viral gene expression using small interfering rna: The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES)... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070149469 - Medical use of tbk-1 or of inhibitors thereof: The present invention relates to a novel angiogenic factor, TBK-1, we well as to inhibitors thereof and to their use in pharmaceutical or diagnostic compositions.... Agent: Clark & Elbing LLP

20070149468 - Methods and compositions for rna interference: The invention provides methods and compositions for gene silencing by RNA interference. In particular, the invention provides methods for gene silencing or RNA knockdown using small interfering RNAs (siRNAs) having partial sequence homology to its target gene. The invention also provides methods for identifying common and/or differential responses to a... Agent: Jones Day

20070149474 - Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia: The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a Chlamydia genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses. The ability of an... Agent: Andrus, Sceales, Starke & Sawall, LLP

20070149473 - Rnai-mediated inhibition of rho kinase for treatment of ocular disorders: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.... Agent: Gloria L. Norberg Winstead Sechrest & Minick P.C.

20070149476 - Combination comprising combretastatin and anticancer agents: An antitumor combination comprising a stilbene derivative and an anticancer compound selected from the group consisting of taxanes, alkylating agents, antimetabolites, vinca alkaloids, platinum compounds, epidophylloptoxins, and antibiotics as the active ingredients is provided. Methods of using these pharmaceutical preparations for the treatment of solid carcinomas and the like are... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149478 - Compositions of plant carbohydrates as dietary supplements: Compositions of plant carbohydrates for dietary supplements and nutritional support for promotion and maintenance of good health. Defined nutritionally effective amounts of one to eleven essential saccharides, glyconutrients, are used in various inventive compositions as dietary supplements. The dietary composition herein can include phytonutrients, vitamins, minerals, herbal extracts, and other... Agent: Haynes And Boone, LLP

20070149477 - Immunomodulatory methods using oligosaccharides: Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokine that regulates development of a T helper... Agent: Lahive & Cockfield, LLP

20070149479 - Nanoparticulate inclusion and charge complex for pharmaceutical formulations: A Nanoparticulate inclusion and charge complex that comprises at least two complex partners, whereby a complex partner is an anionic inclusion-forming agent and another complex partner is a cationic active ingredient.... Agent: Millen, White, Zelano & Branigan, P.C.

20070149480 - Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye: The present invention relates to development of efficacious pharmaceutical compositions comprising an anti-angiogenic compound in a therapeutically effective amount complexed with or encapsulated in a cyclodextrin derivative.... Agent: Alcon

20070149481 - N,n-bridged, nitrogen-substituted carbacyclic indolocarbazoles as protein kinase inhibitors: The present invention relates to novel protein kinase inhibitors with advantageous pharmaceutical properties, methods for their preparation, intermediates thereof and pharmaceutical compositions comprising the same, reagents containing the same, and methods of using the same as therapeutics, particularly in CNS diseases.... Agent: Edwards Angell Palmer & Dodge LLP

20070149482 - Phosphonium salts and their method of preparation: A primary phosphine or a secondary phosphine is reacted with an ester compound selected from the group consisting of; a phosphate triester; a phosphonate diester; a sulfate diester; and a sulfonate ester, to form a phosphonium salt of formula (VII) wherein each of RQ, RX, RY, and RZ is independently... Agent: Cytec Industries Inc.

20070149483 - Methods and compounds for modulating triglyceride and vldl secretion: The invention provides uses of autophagocytosis inducing compounds for reducing serum levels of triglycerides and VLDL and the preparation of medicaments. The invention also provides the use of autophagocytosis inducing compounds for treating hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, atherosclerosis, arteriosclerosis, peripheral artery disease, coronary artery disease, congestive heart failure, myocardial ischemia,... Agent: Womble Carlyle Sandridge & Rice, PLLC

20070149484 - Novel pyridopyrazines and their use as modulators of kinases: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070149485 - Selected dosage for the treatment of cardiovascular and related pathologies: Method is provided of treating or preventing hypertrophy, hypertension, myocardial ischemia, ischemic heart disease, myocardial infarction, congestive heart failure, organ ischemia, tissue ischemia, acute coronary syndrome, unstable angina, ischemia reperfusion injury, preventing death subsequent to myocardial infarction, cerebral infarction, contractile dysfunction subsequent to myocardial infarction, or arrhythmia in a mammal... Agent: Merchant & Gould PC

20070149486 - Process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts: The preset invention relates to a cost effective, high yielding, reproducible method for the manufacture of alendronic acid or its salt, such as sodium alendronate, from inexpensive and readily available pyrrolidone using phosphonating agents such as PCl3 in the presence of acids such as sulphonic acids, sulphuric acid or phosphoric... Agent: Blank Rome LLP

20070149487 - Antiviral compositions and methods: Compositions and methods for treating, preventing, or ameliorating one or more symptoms, conditions, or disorders associated with coronavirus infections are provided, in particular small-molecule inhibitors of the chymotrypsin-like cysteine protease of SARS CoV.... Agent: Fish & Richardson P.C.

20070149488 - Tetracycline derivatives and methods of use thereof: A treatment for inhibiting microbial or tumor growth is disclosed, which comprises adding to a subject in need of treatment an effective amount of one or more tetracycline derivatives.... Agent: Diamond Law Office LLC

20070149489 - Preparation of paricalcitol: The present invention is directed to a novel process for preparing Paricalcitol wherein Paricalcitol, dissolved in a solvent, is precipitated from a concentrated or seeded solution.... Agent: Kenyon & Kenyon LLP

20070149490 - process for the extraction of betulinic acid: Disclosed are large-scale industrial processes for obtaining highly pure betulinic acid from ground plane bark. Betulinic acid is 3β-hydroxy-lup-20(29)-ene-28-oic acid of formula... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070149491 - Compounds useful for treating neurodegenerative disorders: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition... Agent: Choate, Hall & Stewart LLP

20070149492 - Method of affecting sleep and sleep-related behaviors: A method of affecting sleep and sleep-related behaviors of a mammal having a diurnal rhythm, by reducing the basal activity of the hypothalamus-pituitary-adrenal axis by administering an effective amount of a sensory regimen is disclosed. Such reduction may be accomplished by reducing at least one of the following: a. the... Agent: Philip S. Johnson Johnson & Johnson

20070149493 - Sustained release hydrocortisone treatment: We describe a treatment regime for the treatment of conditions which result from the abnormal secretion of cortisol.... Agent: Klarquist Sparkman, LLP

20070149494 - Method for producing 5alpha-pregnane derivative:

20070149495 - Histone deacetylase inhibitors: R5 is selected from the group consisting of a carbonyl, a substituted or unsubstituted C1-3 alkyl, a substituted or unsubstituted —C1-3 alkyl-C(O), a substituted or unsubstituted —C(O)—C1-3 alkyl, and a substituted or unsubstituted —C(O)C(O)C1-3 alkyl; M is a substituent capable of complexing with a protein metal ion; and L is... Agent: Takeda San Diego, Inc.

20070149496 - Water-soluble compound: A water-soluble magnetic anti-mitotic compound with a water-solubility of at least 100 micrograms per milliliter, a molecular weight of at least 150 grams per mole, a mitotic index factor of at least 10 percent, a positive magnetic susceptibility of at least 1,000×10−6 cgs, and a magnetic moment of at least... Agent: Michael L. Weiner Technology Innovations

20070149498 - Cancer therapy: The present invention relates, in general, to cancer therapy, and, in particular, to a method of preventing or treating cancer using low molecular weight antioxidants (e.g., mimetics of superoxide dismutase (SOD)) as the active agent or as a chemo- and/or radio-protectant. The invention also relates to compounds and compositions suitable... Agent: Paul, Hastings, Janofsky & Walker LLP

20070149497 - Water soluble tetrapyrollic photosensitizers for photodynamic therapy: or a pharmaceutically acceptable derivative thereof, wherein R1-R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection... Agent: Simpson & Simpson, PLLC

20070149499 - Process for preparing beta-lactamase inhibitors: The present invention relates to processes for preparing β-alkylidene penem derivatives that can be important as broad spectrum β-lactamase inhibitors and anti-bacterial agents.... Agent: Wilmerhale/wyeth

20070149501 - Process for the preparation of diphenyl azetidinone derivatives: The present invention is a process for the preparation of diphenylazetidinone derivatives of the formula (I) or forms thereof comprising the substituents X, R1 and/or R2 as defined herein. More specifically, the invention comprises methods for the preparation of these compounds by cyclization of certain □-amino carboxamides or □-amino carboxylic... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149503 - Anti-migraine spirocycles: as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as... Agent: Louis J. Wille Bristol-myers Squibb Company

20070149500 - Compounds, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149502 - Spirocyclic anti-migraine compounds: as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as... Agent: Louis J. Wille Bristol-myers Squibb Company

20070149504 - Use of neurokinin antagonists in the treatment of urinary incontinence: This invention relates to compounds of formula I, wherein the R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, and, in particular, their use as pharmaceuticals, e.g. use in urinary incontinence.... Agent: Novartis Corporate Intellectual Property

20070149505 - Method of inhibiting adhesion formation: This invention relates to the use of a vitronectin receptor antagonist to inhibit adhesion formation.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070149506 - Azepine inhibitors of janus kinases: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20070149507 - Process for preparing oxcarbazepine: e

20070149508 - Six membered heteroaromatic inhibitors targeting resistant kinase mutations: wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated... Agent: Dla Piper US LLP

20070149509 - Use of vitamin e: Vitamin E is useful for facilitating the synchronization of circadian rhythm in humans, especially for treatment or prevention of jet lag.... Agent: Nixon & Vanderhye, PC

20070149510 - Quinazolinone and benzoxazinone derivatives and uses thereof: t

20070149512 - N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions: The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.... Agent: Crowell & Moring LLP Intellectual Property Group

20070149511 - Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof: The invention relates to compounds of formula (I), where the groups have the meanings set forth herein and the physiologically-acceptable salts thereof. The compounds are suitable as medicaments for lowering blood sugar levels and for prevention and treatment of diabetes.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149513 - Vanilloid receptor ligands and their use in treatments: Substituted pyridines and pyrimidines and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints... Agent: Amgen Inc.

20070149515 - 6-(2,4,6-trifluorophenyl)-triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungi, and substances containing the same: X is cyano, C1-C4-alkoxy, C3-C4-alkenyloxy, C1-C2-haloalkoxy or C3-C4-halo-alkenyloxy; process for the preparation of these compounds, preparations comprising them and their use in the control of harmful phytopathogenic fungi.... Agent: Birch Stewart Kolasch & Birch

20070149514 - Indole-phenylsulfonamide derivatives used as ppar-delta activating compounds: The invention relates to novel indole-phenylfulfonamide derivatives, to methods for the production thereof, and to their use in medicaments, particularly as potent PPAR-delta activating compounds, for the prevention and/or treatment of cardiovascular diseases, particularly dyslipidemias and coronary heart diseases.... Agent: Jeffrey M. Greenman

20070149517 - 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (vri) activity: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents... Agent: Leydig Voit & Mayer, Ltd

20070149516 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149518 - Oxazoloisoquinoline derivatives as thrombin receptor antagonists: represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein An, Mn, Un, Gn, Jn, Kn, R9, R10, R11, R32, R33, B and Het are herein defined and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070149519 - Benzimidazol substituted thiopene derivatives with activity on ikk3: and compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such benzimidazole derivatives are potentially useful in the treatment of diseases associated with inappropriate I-kappa-B kinase-3 (IKK3) (also known as I-kappa-B kinase epsilon (IKKε) or inducible I-kappa B... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070149520 - Hcv inhibitors and methods of using them: The present invention comprises tetrazoloquinoline-compounds that are inhibitors of HCV. Compositions comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070149521 - Bicyclic protein kinase inhibitors: and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit protein kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions... Agent: Osi Pharmaceuticals, Inc.

20070149522 - Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide: The invention relates to a method for producing 5-chloro-N-({5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide starting from 5-chlorothiophene-2-carbonyl chloride, (2S)-3-amino-propane-1,2-diol and 4-(4-aminophenyl)-3-morpholinone.... Agent: Jeffrey M. Greenman

20070149523 - Thiazole analogues and uses thereof:  wherein the dotted line represents a single or double bond; * indicates the point of attachment to the thiazole ring; and n is 1, 2, or 3. Also disclosed are pharmaceutical compositions comprising the above compounds and method of treatments for cancer and other diseases.... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing 32nd Floor

20070149524 - Substituted diketopiperazines and their use as oxytocin antagonists: x

20070149526 - Diuretic and diuretic-like compound analogs: The present invention provides compounds that are effective in treating central nervous system disorders and maintaining normal brain function. Methods of making and using the compounds are also provided.... Agent: Myers Bigel Sibley & Sajovec

20070149525 - Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149527 - New treatments for nervous disorders: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a... Agent: Warner-lambert Company

20070149532 - 3-aminocyclopentanecarboxamides as modulators of chemokine receptors: i

20070149529 - Amino heterocyclic modulators of chemokine receptor activity: Compounds of Formula I and Formula II: (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R33, R34, R35, R36, R37, R38, A, j, k, m, n, X, Y and Z are as defined herein)... Agent: Merck And Co., Inc

20070149530 - Antiviral agents: m

20070149531 - Antiviral agents:

20070149533 - Bicyclic compounds with kinase inhibitory activity: The present invention provides novel bicyclic compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20070149528 - Triazine dimers for the treatment of autoimmune diseases: Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia... Agent: Nixon & Vanderhye, PC

20070149534 - Pyrrolotriazine kinase inhibitors: m

20070149536 - Inhibitors of akt activity: The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.... Agent: Merck And Co., Inc

20070149535 - Protein kinase inhibitors: e

20070149537 - Nk1 and nk2-antagonists and compositions and methods of using the same:

20070149538 - Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions... Agent: Wilson Sonsini Goodrich & Rosati

20070149539 - Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl }-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to... Agent: Novartis Corporate Intellectual Property

20070149540 - Crystals of quinolinecarboxylic acid derivative solvate: A main object is to provide a crystal of 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid acetonitrile solvate (Compound B) which is an intermediate for producing preferentially the type III crystal of 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl]-4-oxo-4H-[1,3]-thiazeto[3,2-a]quinoline-3-carboxylic acid (Compound A). A crystal of Compound B can be preferentially precipitated by controlling the supersaturation concentration in crystalization using acetonitrile as... Agent: Darby & Darby P.C.

20070149541 - Imidazole compounds: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20070149542 - Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission: i

20070149543 - Agents for treating neurodegenerative diseases: The present invention relates to compounds effective in preventing neuronal cell death, which may be used in the treatment of neurodegenerative diseases. It is based, at least in part, on the discovery that particular compounds were effective in preventing neuronal death in model systems of Huntington's Disease.... Agent: Baker Botts L.L.P.

20070149544 - Biaryl nitrogen-heterocycle inhibitors of lta4h for treating inflammation: e

20070149545 - Substituted indan derivatives: R9 is H, C1-C6 alkyl, C3-C6 cycloalkyl, OCF3, OCHF2, OCH2F, halogen, CN, CF3, OH, C1-C6 alkoxy, C1-C6 alkoxy-C1-C6 alkyl, NR6R7, SO3CH3, SO3CF3, SO2NR6R7, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C1-C6 alkyl; or COR8; wherein... Agent: White & Case LLP Patent Department

20070149548 - (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions: Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising... Agent: Alcon

20070149546 - 4-anilino-quinazoline derivatives as antiproliferative agents: A quinazsoline derivative of the formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrxosine kinase in a warm blooded animnal such as man.... Agent: Morgan Lewis & Bockius LLP

20070149547 - Bipyridyl amides as modulators of metabotropic glutamate receptor-5: The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders,... Agent: Merck And Co., Inc

20070149549 - Prenylation inhibitors and methods of their synthesis and use: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.... Agent: Sheridan Ross PC

20070149551 - 5-phenylpyrimidines, their preparation, compositions comprising them and their use: in which Ra, Rb and Rc are as defined in the description; X is halogen, alkyl, alkoxy or haloalkyl; and m is an integer from 1 to 5; processes for preparing these compounds, compositions comprising them and their use for controlling harmful fungi are described.... Agent: Novak Druce Deluca & Quigg, LLP

20070149550 - Substituted arylpyrazoles: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.... Agent: Warner-lambert Company

20070149552 - Lyophilized compositions of a triazolopyrimidine compound: The present invention relates to lyophilized compositions of a triazolopyrimidine compound, or a hydrate thereof, or a pharmaceutically acceptable salt of Compound I or hydrate thereof; solutions useful in preparing said lyophilized compositions; methods for preparing such compositions; methods of reconstituting the same; kits containing such compositions; and uses of... Agent: Wilmerhale/wyeth

20070149553 - Mitotic kinesin inhibitors: The present invention relates to 2-phenylthienylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20070149554 - Cancer chemotherapy: each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, (CH2)mC(O)N(OR)R′, N(OR)R′, or R1 and R2 together, R3 and R4 together,... Agent: Osha Liang L.L.P.

20070149555 - Prophylatic and/or therapeutic agents for chronic musculoskeletal pain: A prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain comprising as an active ingredient a compound having an adenosine A2A receptor antagonistic action, for example, represented by the following formula (I) (wherein R1, R2 and R3 are the same or different, each representing a hydrogen atom, lower... Agent: Fitzpatrick Cella Harper & Scinto

20070149556 - Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase: (wherein, C ring is nitrogen-containing aromatic heterocyclic ring in which at least one atom in atoms neighboring the atom bound to the pyrimidine ring is unsubstituted nitrogen atom; R10 is hydrogen or lower alkyl; D ring is aryl or heteroaryl) Z1 and Z3 each is independently a single bond, O,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070149558 - Benzo-fused 5-membered heterocyclic compounds, their production and use: (wherein, R1 and R2 are the same or different and each represents a hydrogen atom, hydrocarbon group or heterocyclic group, or R1 and R2 may form, together with the adjacent carbon atom, a 3-8 membered iso- or heterocyclic group, R3 represents a cyclic group, a hydroxy group, a mercapto group... Agent: Takeda Pharmaceuticals North America, Inc Intellectual Property Department

20070149557 - Cxcr3 antagonists: Compounds, compositions and methods are provided that are useful in the treatment of conditions and diseases mediated by a chemokine receptor. In particular, the compounds of the invention modulate the CXCR3 chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as... Agent: Amgen Inc.

20070149559 - Process for reducing contaminating michael acceptor levels in oxycodone and other compositions: The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael... Agent: Wolf Greenfield & Sacks, P.C.

20070149560 - Novel fused triazolones and the uses thereof: This invention relates to novel compounds having the structural diagram (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.... Agent: Astrazeneca R&d Boston

20070149561 - Azaindole inhibitors of aurora kinases: i

20070149562 - Oxopiperidine derivatives, preparation and therapeutic use thereof: The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149563 - New compounds: e

20070149564 - Estrogen modulators: The present application is directed to a new class of isoxazoles and their use as estrogen modulators.... Agent: Warner-lambert Company

20070149565 - Nelfinavir conjugates and antibodies useful in immunoassay: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal... Agent: Marilyn L. Amick Roche Diagnostics Corporation

20070149566 - Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies: t

20070149567 - Quinoline compounds: Quinoline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol... Agent: Pfizer Inc.

20070149569 - Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149568 - N-substituted nonaryl-heterocyclic nmda/nr2b antagonists: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMD NR2B antagonists useful for treating conditions such as, for example, Parkinson's disease, Alzheimer's disease, migraine, epilepsy and pain.... Agent: Merck And Co., Inc

20070149570 - Piperidine derivative and use thereof: or a salt thereof. The compound of the present invention has a superior tachykinin receptor antagonistic action, particularly a substance P receptor antagonistic action, and is useful as a pharmaceutical agent, for example, tachykinin receptor antagonist, an agent for the prophylaxis or treatment of lower urinary tract symptoms, gastrointestinal diseases... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070149571 - Combination therapy for treating or managing acute myelocytic leukemia: The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other... Agent: Jones Day

20070149572 - Method of inhibiting flt3 kinase: e

20070149573 - S-omeprazole magnesium: The present invention discloses a process for preparing a magnesium salt of S-omeprazole. The S-omeprazole salt preferably has a water content below about 4.8% by weight, a magnesium content of about 3.4-4.0% by weight, calculated on the weight of anhydrous, solvent free S-omeprazole magnesium, and has an optical purity of... Agent: Novartis Corporate Intellectual Property

20070149574 - Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein: A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070149575 - 5-aminoalkylpyrazole derivatives as pesticidal agents: The invention relates to 5-aminoalkylaminopyrazole derivatives of formula (I) or salts thereof: wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Frommer Lawrence & Haug

20070149576 - Means for protecting against technical materials: e

20070149577 - Compounds with medicinal effects due to interaction with the glucocorticoid receptor: wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4... Agent: Akzo Nobel Inc.

20070149578 - Combination therapy: This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and statins or pharmaceutically acceptable salts thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting... Agent: Connolly Bove Lodge & Hutz, LLP

20070149579 - Novel pharmaceutical compounds: i

20070149580 - Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases: A method for treating demyelinating diseases in a patient in need thereof by treatment with an effective amount of a PPAR delta agonist is disclosed. Demyelinating diseases that may be effectively treated by this method include but are not limited to multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica,... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149581 - Potent immunosuppressive agents derivatives and use: Provided herein include compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as desmethyl, desamino-pateamine A. Suitable analogs provide anticancer and antiproliferative effects in vivo and... Agent: Gardere Wynne Sewell LLP Intellectual Property Section

20070149582 - 1-(azolin-2-yl)amino-1,2-diphenylethane compounds for combating insects, arachnids and nematodes: The present invention relates to 1-(azolin-2-yl)amino-1,2-diphenylethane compounds of the general formula (I) wherein A is a radical of the formulae A′ or A2: N R A′ A2 and wherein m is 0, 1, 2, 3, 4 or 5, n is 0, 1, 2, 3, 4 or 5, X is sulfur... Agent: Hutchison & Mason

20070149583 - Diazonamide a analog: A specific diazonamide A analog and its salts and conjugates are effective in treating proliferative diseases.... Agent: Morrison & Foerster LLP

20070149584 - Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149585 - Compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists: 3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT1A receptor (agonizing or antagonizing) in a patient. These compounds are further useful for inhibiting binding to a serotonin receptor. Methods of using the 3-amino chroman and 2-amino... Agent: Wilmerhale/wyeth

20070149586 - New crystalline and stable form of andolast: Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary... Agent: Sughrue Mion, PLLC

20070149587 - Valsartan salts: The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.... Agent: Novartis Corporate Intellectual Property

20070149588 - 6-(2,3,6-trifluorophenyl)triazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds: The invention relates to 6-(2,3,6-trifluorophenyl)-triazolopyrimidines of formula (I), in which the substituents are defined as follows: R1 represents alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkenyl, haloalkenyl, cycloalkenyl, halocycloalkenyl, alkynyl, haloalkynyl or phenyl, naphthyl, or a five- or six-membered saturated, partially unsaturated or aromatic heterocycle, containing one to four heteroatoms from the group... Agent: Birch Stewart Kolasch & Birch

20070149589 - Process for the preparation of 4-(benzimidazolylmethylamino)benzamidines: A process for preparing an optionally substituted 4-benzimidazol-2 -ylmethylamino)benzamidine, the process comprising: (a) condensing an optionally suitably substituted diaminobenzene with 2-[4-(1,2,4 -oxadiazol-5-on-3-yl)phenylamino]acetic acid; (b) hydrogenating the product obtained from step (a); and (c) optionally carboxylating the amidino group of the product obtained from step (b).... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070149591 - Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury: Methods and compositions for the treatment of reduced blood flow to the central nervous system are provided. The method comprises administering to a subject a composition having a cyclooxygenase-2 selective inhibitor in combination with applying hypothermic conditions to the subject to provide improved neurological function in subjects with ischemic mediated... Agent: Pharmacia Corporation Global Patent Department

20070149590 - Controlled release dosage form of pirazole compounds: The present invention refers to a pharmaceutical composition for oral administration of pirazole compounds.... Agent: Cooper & Dunham, LLP

20070149593 - Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye: The present invention relates to development of efficacious intravitreal pharmaceutical compositions comprising a poorly water soluble agent with anti-angiogenic and/or anti vascular leakage properties in a therapeutically effective amount and a co-solvent in a suitable amount to treat or prevent diseases due to ocular neovascularization and enhanced vascular permeability. Other... Agent: Alcon

20070149592 - Targeting gli proteins in human cancer by small molecules: This invention provides compositions, methods and kits for the diagnosis and treatment of cancers expressing a GLI polypeptide, and in particular a GLI1, GLI2 or GLI3 polypeptide. The invention provides small molecule compounds mimicking the transcriptional activation domain of a GLI polypeptide. The small molecule inhibitors of the invention specifically... Agent: Townsend And Townsend And Crew, LLP

20070149595 - Compounds having lysophosphatidic acid receptor antagonism and uses thereof: (wherein the symbols in formula were described in the description), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention binds to and is antagonistic to an LPA receptor (particularly, EDG-2), it is useful for prevention and/or treatment of urinary system disease (prostatic... Agent: Sughrue Mion, PLLC

20070149597 - Medicinal composition as immunosuppressant: wherein R1 and R2 each represents hydrogen; R3 represents lower alkyl or hydroxymethyl; R4 represents hydrogen, alkyl, alkoxy or halogen; R5 represents hydrogen, halogeno, cyclohexyl or phenyl; X represents vinylene (CH═CH), oxygen, sulfur or methylated nitrogen; Y represents a single bond, oxygen, sulfur or carbonyl; Z represents a single bond... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070149594 - Pyrrole derivatives: Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim 1, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumours... Agent: Millen, White, Zelano & Branigan, P.C.

20070149596 - Pyrrole derivatives, their preparation and their therapeutic use: m

20070149598 - M3 muscarinic acetylcholine receptor antagonists: Novel thiazole aniline compounds, pharmaceutical compositions, methods of making them and uses thereof in treating M3 muscarinic acetylcholine receptor mediated diseases are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070149599 - Polymorphs of bicifadine hydrochloride: A new polymorphic crystalline form of bicifadine hydrochloride, designated form B, which is more thermodynamically stable than the previously known polymorphic form of bicifadine hydrochloride, designated as form A, methods for preparing said crystalline form B and pharmaceutical compositions containing said crystalline form B.... Agent: Jeffrey J. King Black Lowe & Graham PLLC

20070149601 - Bis-indole pyrroles useful as antimicrobials agents: Compounds of Formula I, commonly referred to as bis-indole pyrroles, including isolated naturally-occurring compounds, synthetic and semi-synthetic derivatives thereof having antimicrobial properties and to antimicrobial compositions that include one or more of bis-indole pyrroles and their derivatives or analogs having antimicrobial properties are disclosed. Pharmaceutical compositions comprising such compounds and... Agent: Knobbe Martens Olson & Bear LLP

20070149602 - N-(1h-indolyl)-1h-indole-2-carboxamide derivatives, their preparation and their therapeutic use: m

20070149600 - Substituted octahydroisoindoles:

20070149603 - Ppar active compounds: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.... Agent: Foley & Lardner LLP

20070149604 - Novel method for preparation of crystalline perindopril erbumine: in a solvent selected from N,N-dimethylformamide, dimethyl acetals of lower aliphatic aldehydes, dimethyl ketals of lower aliphatic ketones and 1,2-dialkoxyethane with tertiary butylamine and crystallization of the erbumine salt thus obtained by heating the reaction mixture to reflux, filtering hot, cooling gradually to 20° C. to 30° C., and further... Agent: Volpe And Koenig, P.C.

20070149605 - Substituted pyrrole derivatives as hmg-coa reductase inhibitors: The present invention relates to substituted pyrrole derivatives of Formula (I), wherein (Y), with the proviso that one of R2, R4 and R5 is a heterocycle and with the further provision that if R2 is not a heterocycle then either R4 or R5 alone is not unsubstituted pyridyl, which can... Agent: Ranbaxy Inc.

20070149606 - Process for producing phenylacetic acid derivative: e

20070149608 - 3-(4-benzyloxyphenyl) propanoic acid derivatives: The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070149607 - Method for producing pyrrolidine derivative: e

20070149609 - Di(amido-substituted)heteroarene compounds as osteoblastogenesis agents: The present invention relates to di(amido-substituted)-heteroarene compounds and their use as osteoblastogenesis agents. The invention provides a method for inducing osteogenesis in a precursor cell capable of undergoing osteogenesis.... Agent: Cooper & Dunham, LLP

20070149610 - Novel compounds from garcinia hanburyi, their use in treating cancer and method of separating epimers thereof: Three pairs of C-2 epimeric xanthones isolated from Garcinia hanburyi and method for efficiently separating the xanthone compounds into individual epimers, each of which possesses varying biological effects. The compounds are useful for their anticancer effects, particularly because they are shown to be non-substrates of the multidrug-resistance transporter. Some of... Agent: Evan Law Group LLC

20070149611 - Cb-delta8-thc composition: An anti-emetic composition comprising Δ8-tetrahydrocannabinol and cannabidiol and the use thereof is described.... Agent: Ade & Company Inc.

20070149612 - Process for preparation of racemic nebivolol:

20070149613 - Fumagillol derivative and the medical use thereof: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angiogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease,... Agent: Bachman & Lapointe, P.C.

20070149614 - Guanidine and amidine acid derivatives and analogs and methods of using the same: The present invention relates to certain novel guanidine or amidine acid derivatives and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20070149615 - Ketone compounds and compositions for cholesterol management and related uses: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing... Agent: Warner-lambert Company

20070149616 - C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h: The present invention provides methods for identifying a patient at risk for developing AMD by identifying the presence of the Y402H polymorphism or other at risk variants in the complement factor H gene. The present invention further provides methods for treating persons having AMD or at risk for developing AMD... Agent: Alcon

20070149617 - Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs: The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein... Agent: Kenyon & Kenyon LLP

20070149618 - Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea;... Agent: Ladas & Parry

20070149619 - Anti-aging agent: Administration of cystine or a salt thereof and theanine or a salt thereof is effective for retarding the progress of aging and reducing the effects of aging.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070149620 - Use of piketprofen for the preparation of a pharmaceutical composition to treat rosacea: The present invention relates to the use of piketoprofen for the preparation of novel pharmaceutical compositions and more particularly dermatological compositions that are useful for treating rosacea.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070149621 - 11beta-benzaldoxime derivatives of d-homooestra-4,9-dien-3-ones: R2 is a hydrogen atom or a C1-C6-alkyl or C1-C6-acyl group. Compounds of formula I bind more strongly to the glucocorticoid receptor than to the progesterone receptor and are effective antiglucocorticoids. According to the invention, they are suitable for the treatment and/or prevention of symptoms and/or diseases that are attributable... Agent: Millen, White, Zelano & Branigan, P.C.

20070149622 - Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic... Agent: Knobbe Martens Olson & Bear LLP

20070149623 - Therapeutic formulation: A pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and, optionally, an acetogenin. The formulation demonstrates positive effects against cancer, autoimmune disease, viruses and provides antioxidant protection against peroxyl, hydroxyl and super oxide radicals.... Agent: Thomas Moga Butzel Long

20070142313 - Microrna1 therapies: Delta protein expression in a cell is reduced by introducing miR-1 into the cell, and detecting a resultant reduction of Delta protein expression in the cell.... Agent: Richard Aron Osman Science And Technology Law Group

20070142266 - Combination comprising a p-gp inhibitor and an anti-epileptic drug: The invention relates to a combination which comprises a P-glycoprotein (P-gp) inhibitor and an antiepileptic drug selected from phenytoin (5,5-diphenyl-2,4-imidazolidinedione), carbamazepine, lamotrigine, gabapentin, oxcarbazepin, valproic acid, and topiramate, and its use for the prevention, delay of progression or treatment of diseases, in particular epilepsy, especially epilepsy which is resistant to... Agent: Novartis Corporate Intellectual Property

20070142267 - Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells: The present invention relates to a composite for the treatment of a variety of medical conditions, the composite comprising an oxidized glutathione-based compound, which has a disulfide bond, and a metal material, in particular where the metal is either platinum or palladium. The oxidized glutathione-based compound and metal material can... Agent: Wolf Greenfield & Sacks, P.C.

20070142268 - Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif: e

20070142270 - Aryl sulfonic pyridoxines as antiplatelet agents: Aryl sulfonic pyridoxine compounds with inhibition of serine protease activity and antiplatelet aggregation characteristics for the treatment of cardiovascular and cardiovascular related diseases are described. The methods are directed to administering pharmaceutical compositions comprising aryl sulfonic pyridoxines.... Agent: Merchant & Gould PC

20070142269 - Oligopeptide, derivatives thereof, and pharmaceutical composition comprising the same: y

20070142279 - Agent for promoting induction of vascular differentiation, comprising hepatocyte growth factor: The present invention provides an agent for promoting induction of differentiation of bone marrow cells into endothelial progenitor cells capable of being differentiated into endothelial cells, comprising hepatocyte growth factor as an active ingredient, and such agent is useful in the field of medical therapy or regenerative medicine.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070142283 - Angiogenically effective unit dose of fgf-2 and method of use: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another... Agent: Novartis Vaccines And Diagnostics Inc.

20070142277 - Bace455, an alternative splice variant of the human beta-secretase: The present invention relates generally to the fields of genetics, biochemistry, medicinal chemistry and medicine. The present invention more particularly discloses the identification of a human gene variant involved in neuropathological conditions, and methods for the diagnosis, prevention and treatment of such diseases and related disorders, as well as for... Agent: Hunton & Williams LLP Intellectual Property Department

20070142292 - Composition of lactoferrin related peptides and uses thereof: The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.... Agent: Fulbright & Jaworski, LLP

20070142287 - Compositions and methods for treatment of cancer: The present invention provides a pharmaceutical composition that includes a) one or both of i) a peptide ligand that binds a zeta receptor and ii) at least one cancer chemotherapeutic agent; and b) a sustained release formulation. The invention also provides a combination including at least a portion of a... Agent: Proteus Patent Practice LLC

20070142280 - Factor vii or viia-like molecules: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.... Agent: Maxygen, Inc. Intellectual Property Department

20070142274 - Fish protein hydrolyzate: The present invention relates to the use of a enzyme treated fish protein hydrolyzate (FPH). The FPH material lowers the concentration of cholesterol in plasma, and triglycerides in the liver. FPH also induces a favourable change in the fatty acid pattern, and lowers the concentration of homocysteine in plasma. A... Agent: Reed Smith LLP

20070142294 - Identification and cloning of novel human gene, ret16, involved in the intracellular signaling cascade: The present invention describes a newly discovered polynucleotide encoding a protein involved in the cell signaling cascade, called RET16, cloned, isolated and identified from TNF-alpha stimulated human microvascular endothelial cells, as well as mouse and rat RET16 orthologs thereof. Also described are the RET16 polypeptide sequence, expression vectors, host cells,... Agent: Louis J. Wille Bristol-myers Squibb Company

20070142288 - Isolated mcpip and methods of use: A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed.... Agent: Donna J. Russell

20070142273 - Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis: The invention discloses that members of a subfamily of receptor tyrosine kinases comprising TYRO3, Axl, cMer and ligands thereof, such as GAS6 are suitable targets for the development of new therapeutics to treat, prevent or ameliorate OA. The invention also relates to methods to treat and/or ameliorate OA and pharmaceutical... Agent: Novartis Corporate Intellectual Property

20070142291 - Methods for treating irritable bowel syndrome: Disclosed is a method of manipulating the rate of upper gastrointestinal transit